Lipoxen awarded PATH funding for malaria study
This article was originally published in Scrip
Lipoxen has received funding from the PATH Malaria Vaccine Initiative for a feasibility study to test whether its ImuXen technology will enhance the performance of malaria vaccine candidates. The amount was not disclosed.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.